A combination of alpha lipoic acid and calcium hydroxycitrate is efficient against mouse cancer models: Preliminary results

  • Authors:
    • Laurent Schwartz
    • Mohammad Abolhassani
    • Adeline Guais
    • Edward Sanders
    • Jean-Marc Steyaert
    • Frederic Campion
    • Maurice Israël
  • View Affiliations

  • Published online on: Saturday, May 1, 2010
  • Pages: 1407-1416
  • DOI: 10.3892/or_00000778

Abstract

The impact of metabolic dysregulation on tumor development has long been established. We have targeted two enzymes that are altered during carcinogenesis: pyruvate dehydrogenase (PDH), which is down-regulated, and ATP citrate lyase, which is overexpressed in cancer cells. Alpha lipoic acid is a cofactor of PDH, while hydroxycitrate is a known inhibitor of ATP citrate lyase. Our hypothesis is that a combination of these drugs may have antitumoral potential. The efficacy of these molecules was screened in vitro by treatment of different human cancer and murine cell lines. Lipoic acid reduced the cell number by 10-50% depending on concentrations (0.1-10 µM) and cell types. Calcium hydroxycitrate reduced the cell number by 5-60% at different concentrations (10-500 µM). When hydroxycitrate and lipoic acid were used together, there was a major cytotoxic effect: complete cell death was seen following 8 µM lipoic acid and 300 µM hydroxycitrate treatment for 72 h. The combination of alpha lipoic acid and hydroxycitrate was administered to healthy mice, at doses currently utilized for other indications than cancer; no demonstrable toxicity was observed. The combination was used to treat mouse syngenic cancer models: MBT-2 bladder transitional cell carcinoma, B16-F10 melanoma and LL/2 Lewis lung carcinoma. The efficacy of this combination appears similar to conventional chemotherapy (cisplatin or 5-fluorouracil) as it resulted in significant tumor growth retardation and enhanced survival. This preliminary study suggests that this combination of drugs is efficient against cancer cell proliferation both in vitro and in vivo. A clinical trial is warranted.
Journal Cover

May 2010
Volume 23 Issue 5

Print ISSN: 1021-335X
Online ISSN:1791-2431

2013 Impact Factor: 2.191
Ranked #33/202 Oncology
(total number of cites)

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Schwartz, L., Abolhassani, M., Guais, A., Sanders, E., Steyaert, J., Campion, F., & Israël, M. (2010). A combination of alpha lipoic acid and calcium hydroxycitrate is efficient against mouse cancer models: Preliminary results. Oncology Reports, 23(5), 1407-1416.
MLA
Schwartz, Abolhassani, Guais, Sanders, Steyaert, Campion, and Maurice Israël. "A combination of alpha lipoic acid and calcium hydroxycitrate is efficient against mouse cancer models: Preliminary results." Oncology Reports Oncology Reports 23.5 (2010): 1407-1416.
Chicago
Schwartz, Abolhassani, Guais, Sanders, Steyaert, Campion, and Maurice Israël. "A combination of alpha lipoic acid and calcium hydroxycitrate is efficient against mouse cancer models: Preliminary results." Oncology Reports Oncology Reports 23 no. 5 (2010): 1407-1416.